Pharmaceutical Composition Comprising an Indolylmaleimide Derivative

A solid pharmaceutical composition suitable for oral administration comprising an indolylmaleimide derivative of formula I

• wherein
• Ra is H;
• C1-4alkyl;
• or C1-4alkyl substituted by OH, NH2, NHC1-4alkyl or N(di-C1-4alkyl)2;
• Rb is H;
• or C1-4alkyl;
• R is a radical of formula (a), (b), (c), (d), (e) or (f)
• wherein
• each of R1, R4, R7, R8, R11 and R14 is OH;
• SH;
• a heterocyclic residue;
• NR16R17 wherein each of R16 and R17, independently, is H or C1-4alkyl or R16 and R17 form together with the nitrogen atom to which they are bound a heterocyclic residue;
• or a radical of formula α
• —X—Rc—Y (α)
• wherein X is a direct bond, O, S or NR18 wherein R18 is H or C1-4alkyl,
• Rc is C1-4alkylene or C1-4alkylene wherein one CH2 is replaced by CRxRy wherein one of Rx and Ry is H and the other is CH3, each of Rx and Ry is CH3 or Rx and Ry form together —CH2—CH2—, and
• Y is bound to the terminal carbon atom and is selected from OH, a heterocyclic residue and —NR19R20 wherein each of R19 and R20 independently is H, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkyl, aryl-C1-4alkyl or C1-4alkyl optionally substituted on the terminal carbon atom by OH, or R19 and R20 form together with the nitrogen atom to which they are bound a heterocyclic residue;
• each of R2, R3, R5, R6, R9, R10, R12, R13, R15 and R′15, independently, is H, halogen, C1-4alkyl, CF3, OH, SH, NH2, C1-4alkoxy, C1-4alkylthio, NHC1-4alkyl, N(di-C1-4alkyl)2 or CN;
• either E is —N═ and G is —CH═ or E is —CH═ and G is —N═;
• and
• in free form or in pharmaceutically acceptable salt.